IL1B T-31C and VEGFA C+936T SNPs may be used as prognostic markers of rheumatoid arthritis treatment inefficiency

The aim of our study was to analyze the association between some SNPs and treatment of rheumatoid arthritis with biological drugs. Patients and methods: We studied 368 Russian patients with rheumatoid arthritis. All of them were treated in accordance with the standard recommendations. Fifty seven patient received biological disease-modifying antirheumatic drugs. Single nucleotide polymorphisms (TNFA C-863A, TNFA G-308A, TNFA G-238A, IL1B T-31C, IL4 C-590T, IL6 G-174C, IL10 A-1082G, IL10 C-592A VEGFA C+936T, VEGFA C2578A) were determined by restriction fragment length polymorphism analysis of PCR-amplified fragments (PCRRFLP) or RT-PCR. Results: The IL1B T-31C and VEGFA C+936T SNPs were association with bDMARDs treatment. Homozygotes IL1B - 31CC and VEGFA +936 CC were more frequently in bDMARDs group compare with patients without bDMARDs (28.1% vs 17.1%, p=0.044 and 80.4% vs 66.6%, p=0.041). Other polymorphisms didn't demonstrate any significant differences. Conclusions: Our data suggest, that IL1B T-31C and VEGFA C+936T SNPs can be used as part of a comprehensive assessment of the prognosis of the treatment effectiveness.